Strategically acquiring and approving cancer drugs

A lean, entrepreneurial approach is enabling specialty pharma company EUSA Pharma to outcompete larger rivals.

Go to the profile of EUSA Pharma
Mar 13, 2018
0
0
Page of
Go to the profile of EUSA Pharma

EUSA Pharma

Founded in March 2015, EUSA Pharma is a profitable commercial-stage specialty pharmaceutical company with global reach from its headquarters in the UK and its commercial operations across Europe and the USA. EUSA Pharma has a portfolio of approved Oncology therapeutic and supportive care products including: FOTIVDA® (tivozanib) for the treatment of advanced RCC, QARZIBA® (dinutuximab beta) for the treatment of HR Neuroblastoma, Caphosol® and Caphosol® DISPERSIBLE, for the treatment and prevention of Oral Mucositis.

No comments yet.